Access to anti-retroviral drugs, female in Estonia

Estonia: Access to anti-retroviral drugs, female was 70.0% in 2022. ◆ Volatile

Latest (2022)
70.0%
Change on year
down 2.8%
World rank
82nd
of 141 countries
All-time high
76.0%
in 2019
All-time low
2.0%
in 2002
Years of data
23
2000–2022

Access to anti-retroviral drugs, female in Estonia, 2000–2022

0204060802000201120222000: 14 %2001: 3 %2002: 2 %2003: 2 %2004: 3 %2005: 7 %2006: 11 %2007: 16 %2008: 22 %2009: 27 %2010: 35 %2011: 41 %2012: 47 %2013: 50 %2014: 54 %2015: 62 %2016: 68 %2017: 71 %2018: 74 %2019: 76 %2020: 73 %2021: 72 %2022: 70 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, female in Estonia is 70.0%, measured in 2022.

The figure is down 2.8% on the previous year and up 48.9% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Estonia peaked at 76.0% in 2019 and was at its lowest, 2.0%, in 2002.

That places Estonia 82nd out of 141 countries with data for 2022, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Estonia, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Estonia, 2000 to 2022.
Year % Change
2000 14.0%
2001 3.0% -78.6%
2002 2.0% -33.3%
2003 2.0% +0.0%
2004 3.0% +50.0%
2005 7.0% +133.3%
2006 11.0% +57.1%
2007 16.0% +45.5%
2008 22.0% +37.5%
2009 27.0% +22.7%
2010 35.0% +29.6%
2011 41.0% +17.1%
2012 47.0% +14.6%
2013 50.0% +6.4%
2014 54.0% +8.0%
2015 62.0% +14.8%
2016 68.0% +9.7%
2017 71.0% +4.4%
2018 74.0% +4.2%
2019 76.0% +2.7%
2020 73.0% -3.9%
2021 72.0% -1.4%
2022 70.0% -2.8%

Averages by decade

DecadeAverage LowestHighest Years
2000s 10.7% 2.0% 27.0% 10
2010s 57.8% 35.0% 76.0% 10
2020s 71.7% 70.0% 73.0% 3

Countries ranked near Estonia

  1. 81 Lao People's Democratic Republic 71.0% compare
  2. 82 Somalia 70.0% compare
  3. 84 Lebanon 69.0% compare
  4. 84 Serbia 69.0% compare

See the full ranking of 160 places →

More gender data for Estonia

All data for Estonia →

Frequently asked questions

What is access to anti-retroviral drugs, female in Estonia?
Access to anti-retroviral drugs, female in Estonia was 70.0% in 2022, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Estonia?
The highest recorded value was 76.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Estonia?
The lowest recorded value was 2.0% in 2002.
How does Estonia rank for access to anti-retroviral drugs, female?
Estonia ranks 82nd out of 141 countries with data for 2022.
Is access to anti-retroviral drugs, female rising or falling in Estonia?
Over the last ten years it is up 48.9%. The long-run trend across the full record is volatile.
Where does this Estonia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 23 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Estonia. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/estonia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/estonia/">Access to anti-retroviral drugs, female in Estonia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.